AccScience Publishing / ARNM / Online First / DOI: 10.36922/ARNM025490062
Submit to ARNM
Cite this article
33
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
PERSPECTIVE ARTICLE

Clinical nursing interventions for iodine-123 imaging in radiation oncology: A review

Marina Tatin1*
Show Less
1 Department of Nursing, School of Nursing, North East Christian University, Dimapur, Nagaland, India
ARNM, 025490062 https://doi.org/10.36922/ARNM025490062
Received: 7 December 2025 | Revised: 2 March 2026 | Accepted: 18 March 2026 | Published online: 5 May 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
XML
Cite
Abstract

Iodine-123 (I-123) scintigraphy is a pivotal diagnostic and treatment planning tool in the management of thyroid cancer, neuroendocrine tumors, and certain motor disorders in the context of radiation oncology practice. This perspective article aims to synthesize the existing evidence on nursing interventions related to I-123 scintigraphy, including radiopharmaceuticals, radiation safety, patient education, and psychosocial interventions. It also highlights existing gaps in nursing practice guidelines for I-123 scintigraphy and provides evidence-based recommendations to address them. Well-designed nursing interventions play a crucial role in improving diagnostic image quality, patient compliance, safety, and occupational radiation exposure. With the increasing use of I-123 scintigraphy in theranostic cancer treatment strategies, advanced nursing competencies in nuclear medicine oncology practice are essential.

Keywords
Iodine-123 imaging
Radiation oncology nursing
Nuclear medicine
Radiopharmaceutical care
Patient safety
Theranostics
Funding
None.
Conflict of interest
The author declares no conflicts of interest.
References
  1. Giovanella L, Avram AM, Iakovou I, et al. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. Eur J Nucl Med Mol Imaging. 2019;46(12):2514- 2525. doi: 10.1007/s00259-019-04472-8
  2. Djang DS, Janssen MJ, Bohnen N, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53(1):154-163. doi: 10.2967/jnumed.111.100784
  3. Weatherman K, Grady EE, Mastascusa N, et al. The SNMMI/ACNM Practice Guideline for the Use of Radiopharmaceuticals 5.0. J Nucl Med Technol. 2025;53(2):130-134. doi: 10.2967/jnmt.125.269834
  4. Lego RL. A Perspective on Production and Quality Control of Iodine-123 Radiopharmaceutical for Applications in Nuclear Medicine. Indian J Nucl Med. 2025;40(1):1-9. doi: 10.4103/ijnm.ijnm_104_24
  5. Chang MC, Peng CL, Chen CT, et al. Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review. Pharmaceuticals. 2024;17(12):1563. doi: 10.3390/ph17121563
  6. Moskalenko M, Zaccone J, Fiscelli CA, et al. Assessment of Radiation Oncology Nurse Education in the United States. Int J Radiat Oncol Biol Phys. 2021;110(3):667-671. doi: 10.1016/j.ijrobp.2021.01.031
  7. Harr BA, Hollman J, Johnston M, Dickman E. Findings from the 2023 radiation oncology nursing role delineation study to shape the future of the subspecialty. Clin J Oncol Nurs. 2024;28(6):598-603. doi: 10.1188/24.CJON.598-603
  8. Williams SA. Using Oncology Nursing Society Cancer Chemotherapy Guidelines as a basis for continuing education in rural hospitals. Oncol Nurs Forum. 1995;22(4):689-694.
  9. Faithfull S. Randomized trial, a method of comparisons: a study of supportive care in radiotherapy nursing. Eur J Oncol Nurs. 1999;3(3):176-184. doi: 10.1016/S1462-3889(99)80833-3
  10. Halkett GK, Kristjanson LJ, Lobb E, O’Driscoll C, Taylor M, Spry N. Meeting breast cancer patients’ information needs during radiotherapy: what can we do to improve the information and support that is currently provided?. Eur J Cancer Care. 2010;19(4):538-547. doi: 10.1111/j.1365-2354.2009.01090.x
  11. Kelvin JF, Moore-Higgs GJ, Maher KE, et al. Non-physician practitioners in radiation oncology: advanced practice nurses and physician assistants. Int J Radiat Oncol Biol Phys. 1999;45(2):255-263. doi: 10.1016/s0360-3016(99)00180-7
  12. Carper E, Haas M. Advanced practice nursing in radiation oncology. Semin Oncol Nurs. 2006;22(4):203-211. doi: 10.1016/j.soncn.2006.07.003
  13. Saha GB. Fundamentals of Nuclear Pharmacy. 7th ed. Cham: Springer. 2018. doi: 10.1007/978-3-319-57580-3
  14. Cherry SR, Sorenson JA, Phelps ME. Physics in Nuclear Medicine. 4th ed. Philadelphia, PA: Saunders/Elsevier. 2012.
  15. Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid. 2025;35(8):841-985. doi: 10.1177/10507256251363120.
  16. Tuttle RM, Ahuja S, Avram AM, et al. Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29(4):461-470. doi: 10.1089/thy.2018.0597.
  17. Bombardieri E, Aktolun C, Baum RP, et al. 131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30(12):1. doi: 10.1007/s00259-003-1357-0.
  18. Taïeb D, Hicks RJ, Hindié E, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46(10):2112-2137. doi: 10.1007/s00259-019-04398-1.
  19. Booij J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997 ;62(2):133-140. doi: 10.1136/jnnp.62.2.133
  20. Seibyl J, Jennings D, Tabamo R, Marek K. Neuroimaging trials of Parkinson’s disease progression. J Neurol. 2004;251(S7):vii9 -vii13. doi: 10.1007/s00415-004-1704-5.
  21. Moka D, Dietlein M, Schicha H. Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med Mol Imaging. 2002;29(S2):S486-S491. doi: 10.1007/s00259-002-0868-4.
  22. Mattsson S. Radiation protection of the patient in diagnostic radiology and nuclear medicine. Are we doing enough? In: Proceedings of the 9th International Conference on Medical Physics – Medical Physics in the Baltic States; October 13–15, 2011; Kaunas, Lithuania. Kaunas University of Technology Press; 2011:7-12. Available from: https://portal. research.lu.se/en/publications/radiation-protection-of-the-patient-in-diagnostic-radiology-and-n/ [Last accessed on February 26, 2026].
  23. Gebruers J, Terwinghe C, Graven LH, et al. Extravasation of Therapeutic Radiopharmaceuticals: A Systematic Review and Management Proposal. J Nucl Med. 2025;66(12):1948- 1955. doi: 10.2967/jnumed.125.270215
  24. Williams G, Palmer MR, Parker JA, Joyce R. Case Report: Extravasation of therapeutic yttrium-90-ibritumomab tiuxetan (Zevalin): a case report. Cancer Biother Radiopharm. 2006;21(2):101-105. doi: 10.1089/cbr.2006.21.101
  25. Heston TF, Tafti D. Nuclear medicine safety. In: StatPearls [Internet]. StatPearls Publishing. 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK603730/ [Last accessed on February 26, 2026].
  26. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37(2-4):1-332. doi: 10.1016/j.icrp.2007.10.003
  27. World Health Organization. Enhancing Radiation Safety Culture in Health Care: Guidance for Health Care Providers. WHO. 2024. Available from: https://www.who. int/publications/i/item/9789240091115 [Last accessed on February 26, 2026].
  28. Dowd SB, Tilson ER. Practical Radiation Protection and Applied Radiobiology. Philadelphia: W.B. Saunders Co. 1994. Available from: https://books.google.com.my/ books/about/Practical_Radiation_Protection_and_Appli. html?id=aopuQgAACAAJ&redir_esc=y [Last accessed on February 26, 2026].
  29. Martin CJ. Effective dose: how should it be applied to medical exposures?. Br J Radiol. 2007;80(956):639-647. doi: 10.1259/bjr/25922439
  30. Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53(10):1633-1651. doi: 10.2967/jnumed.112.105148
  31. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(8):2543-2565. doi: 10.1210/jc.2011-2803
  32. Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21(10):1081- 1125. doi: 10.1089/thy.2011.0087
  33. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41(5):863-873. Available from: https://pubmed.ncbi.nlm.nih.gov/10809203/ [Last accessed on February 26, 2026].
  34. Fahey FH, Treves ST, Adelstein SJ. Minimizing and communicating radiation risk in pediatric nuclear medicine. J Nucl Med. 2011;52(8):1240-1251. doi: 10.2967/jnumed.109.069609
  35. Treves ST, Gelfand MJ, Fahey FH, Parisi MT. 2016 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical Activities. J Nucl Med. 2016;57(12):15N-18N. Available from: https://pubmed. ncbi.nlm.nih.gov/27909182 [Last accessed on February 26, 2026].
  36. Lassmann M, Treves ST. Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines. Eur J Nucl Med Mol Imaging. 2014;41(5):1036-1041. doi: 10.1007/s00259-014-2731-9
  37. Gelfand MJ, Parisi MT, Treves ST. Pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines. J Nucl Med. 2011;52(2):318- 322. doi: 10.2967/jnumed.110.084327
  38. Bauer C, Laszewski P, Magnan M. Promoting adherence to skin care practices among patients receiving radiation therapy. Clin J Oncol Nurs. 2015;19(2):196-203. doi: 10.1188/15.CJON.196-203
  39. Halkett G, O’Connor M, Aranda S, et al. Communication skills training for radiation therapists: preparing patients for radiation therapy. J Med Radiat Sci. 2016;63(4):232‑241. doi: 10.1002/jmrs.171
  40. Faithfull S, Cockle-Hearne J, Lemanska A, Otter S, Skene SS. Randomised controlled trial to investigate the effectiveness of the symptom management after radiotherapy (SMaRT) group intervention to ameliorate lower urinary tract symptoms in men treated for prostate cancer. Support Care Cancer. 2022;30(4):3165-3176. doi: 10.1007/s00520-021-06749-x.
  41. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674-1685. doi: 10.1056/NEJMoa1109589
  42. Bolderston A. Mixed messages? A comparison between the perceptions of radiation therapy patients and radiation therapists regarding patients’ educational needs. Radiography. 2008;14(2):111‑119. doi: 10.1016/j.radi.2006.09.001
  43. Sheridan SL, Halpern DJ, Viera AJ, Berkman ND, Donahue KE, Crotty K. Interventions for individuals with low health literacy: a systematic review. J Health Commun. 2011;16(3):30-54. doi: 10.1080/10810730.2011.604391
  44. Nouri SS, Rudd RE. Health literacy in the “oral exchange”: an important element of patient-provider communication. Patient Educ Couns. 2015;98(5):565-571. doi: 10.1016/j.pec.2014.12.002
  45. Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160- 174. doi: 10.1016/S1470-2045(11)70002-X
  46. Carlson LE, Zelinski EL, Toivonen KI, et al. Prevalence of psychosocial distress in cancer patients across 55 North American cancer centers. J Psychosoc Oncol. 2019;37(1):5- 21. doi: 10.1080/07347332.2018.1521490
  47. Leotin S. An Insider View of the Cancer Radiation Experience Through the Eyes of a Cancer Patient. J Patient Exp. 2020;7(2):160-162. doi: 10.1177/2374373519832604
  48. Abel L, Dafoe-Lambie J, Butler WM, Merrick GS. Treatment outcomes and quality-of-life issues for patients treated with prostate brachytherapy. Clin J Oncol Nurs. 2003;7(1):48-54. doi: 10.1188/03.CJON.48-54
  49. Aranda S, Schofield P, Weih L, et al. Mapping the quality of life and unmet needs of urban women with metastatic breast cancer. Eur J Cancer Care. 2005;14(3):211-222. doi: 10.1111/j.1365-2354.2005.00541.x
  50. Probst H, Rosbottom K, Crank H, Stanton A, Reed H. The patient experience of radiotherapy for breast cancer: A qualitative investigation as part of the SuPPORT 4 All study. Radiography. 2021;27(2):352-359. doi: 10.1016/j.radi.2020.09.011
  51. Campinha-Bacote J. The Process of Cultural Competence in the Delivery of Healthcare Services: a model of care. J Transcult Nurs. 2002;13(3):181-184. doi: 10.1177/10459602013003003
  52. Kagawa-Singer M, Dadia AV, Yu MC, Surbone A. Cancer, culture, and health disparities: time to chart a new course?. CA Cancer J Clin. 2010;60(1):12-39. doi: 10.3322/caac.20051
  53. Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med. 2011;155(2):97-107. doi: 10.7326/0003-4819-155-2-201107190-00005
  54. Chan RJ, Webster J, Chung B, Marquart L, Ahmed M, Garantziotis S. Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2014;14(1):53. doi: 10.1186/1471-2407-14-53
  55. Wong RK, Bensadoun RJ, Boers-Doets CB, et al. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer. 2013;21(10):2933-2948. doi: 10.1007/s00520-013-1896-2
  56. McQuestion M. Evidence-based skin care management in radiation therapy: clinical update. Semin Oncol Nurs. 2011;27(2):e1-e17. doi: 10.1016/j.soncn.2011.02.009
  57. Hegedus F, Mathew LM, Schwartz RA. Radiation dermatitis: an overview. Int J Dermatol. 2017;56(9):909-914. doi: 10.1111/ijd.13371
  58. Bolderston A, Lloyd NS, Wong RK, Holden L, Robb- Blenderman L. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer. 2006;14(8):802-817. doi: 10.1007/s00520-006-0063-4
  59. Morley L, Cashell A, Sperduti A, McQuestion M, Chow JCL. Evaluating the relevance of dosimetric considerations to patient instructions regarding skin care during radiation therapy. J Radiother Pract. 2014;13(3):294-301. doi: 10.1017/S1460396913000241
  60. Gosselin TK, Schneider SM, Plambeck MA, Rowe K. A prospective randomized, placebo-controlled skin care study in women diagnosed with breast cancer undergoing radiation therapy. Oncol Nurs Forum. 2010;37(5):619-626. doi: 10.1188/10.ONF.619-626
  61. Bergenmar M, Nylén U, Lidbrink E, Bergh J, Brandberg Y. Improvements in patient satisfaction at an outpatient clinic for patients with breast cancer. Acta Oncol. 2006;45(5):550- 558. doi: 10.1080/02841860500511239
  62. Bower JE. Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597-609. doi: 10.1038/nrclinonc.2014.127
  63. Horneber M, Fischer I, Dimeo F, Rüffer JU, Weis J. Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment. Dtsch Arztebl Int. 2012;109(9):161-172. doi: 10.3238/arztebl.2012.0161
  64. Mustian KM, Alfano CM, Heckler C, et al. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis. JAMA Oncol. 2017;3(7):961-968. doi: 10.1001/jamaoncol.2016.6914
  65. Feyer P, Jahn F, Jordan K. Radiation induced nausea and vomiting. Eur J Pharm. 2014;722:165-171. doi: 10.1016/j.ejphar.2013.09.069
  66. Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(s5):v119-v133. doi: 10.1093/annonc/mdw270
  67. Tian L, Zhang Z, Wu S, Ma J, Tian S, Wang P. Evidence-based nursing practice of radiation-induced oral mucositis in patients with head and neck cancer. Asia Pac J Oncol Nurs. 2025;12:100802. doi: 10.1016/j.apjon.2025.100802
  68. Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68(4):1110-1120. doi: 10.1016/j.ijrobp.2007.01.053
  69. Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126(19):4423- 4431. doi: 10.1002/cncr.33100
  70. Andreyev HJ, Davidson SE, Gillespie C, et al. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut. 2012;61(2):179-192. doi: 10.1136/gutjnl-2011-300563
  71. Wedlake L, Shaw C, McNair H, et al. Randomized controlled trial of dietary fiber for the prevention of radiation-induced gastrointestinal toxicity during pelvic radiotherapy. Am J Clin Nutr. 2017;106(3):849-857. doi: 10.3945/ajcn.116.150565
  72. Davis BJ, Horwitz EM, Lee WR, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012;11(1):6-19. doi: 10.1016/j.brachy.2011.07.005
  73. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44(4):789-799. doi: 10.1016/s0360-3016(99)00069-3
  74. Stipetich RL, Canfield VA, Carroll PR, et al. Nursing assessment of sexual function following permanent prostate brachytherapy for patients with early-stage prostate cancer. Clin J Oncol Nurs. 2002;6(5):271-274. doi: 10.1188/02.CJON.271-274
  75. Krebs LU. Sexual assessment in cancer care: concepts, methods, and strategies for success. Semin Oncol Nurs. 2008;24(2):80‑90. doi: 10.1016/j.soncn.2008.02.002
  76. Reese JB, Sorice K, Beach MC, et al. Patient-provider communication about sexual concerns in cancer: a systematic review. J Cancer Surviv. 2017;11(2):175-188. doi: 10.1007/s11764-016-0577-9
  77. Thomas CW, Bainbridge TC, Thomson TA, McGahan CE, Morris WJ. Clinical impact of second pathology opinion: A longitudinal study of central genitourinary pathology review before prostate brachytherapy. Brachytherapy. 2007;6(2):135-141. doi: 10.1016/j.brachy.2006.10.003
  78. Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005;23(12):2772- 2780. doi: 10.1200/JCO.2005.07.116
  79. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250-1261. doi: 10.1056/NEJMoa074311
  80. Gaither TW, Awad MA, Osterberg EC, et al. The Natural History of Erectile Dysfunction After Prostatic Radiotherapy: A Systematic Review and Meta-Analysis. J Sex Med. 2017;14(9):1071-1078. doi: 10.1016/j.jsxm.2017.07.010
  81. Moon H. Nursing care for women with gynecologic cancerreceiving radiotherapy: current updates. Korean J Women Health Nurs. 2023;29(4):257-262. doi: 10.4069/kjwhn.2023.12.11
  82. Viswanathan AN, Thomadsen B. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy. 2012;11(1):33-46. doi: 10.1016/j.brachy.2011.07.003
  83. Kirchheiner K, Nout RA, Czajka-Pepl A, et al. Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery - a mono-institutional prospective study. Gynecol Oncol. 2015;136(3):415-423. doi: 10.1016/j.ygyno.2014.10.031
  84. Sergieva S, Mihaylova I, Alexandrova E, Dimcheva M, Mansi L. SPECT-CT in Radiotherapy Planning, with Main Reference to Patients with Breast Cancer. Curr Radiopharm. 2015;8(1):9-18. doi: 10.2174/1874471008666150316221722
  85. Pandit-Taskar N, Zanzonico P, Hilden P, Ostrovnaya I, Carrasquillo JA, Modak S. Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging. Clin Nucl Med. 2017;42(10):741-748. doi: 10.1097/RLU.0000000000001752.
  86. Hicks RJ, Hofman MS. Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat Rev Clin Oncol. 2012;9(12):712-720. doi: 10.1038/nrclinonc.2012.188
  87. Grégoire V, Evans M, Le QT, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018;126(1):3-24. doi: 10.1016/j.radonc.2017.10.016
  88. Thorwarth D. Functional imaging for radiotherapy treatment planning: current status and future directions-a review. Br J Radiol. 2015;88(1051):20150056. doi: 10.1259/bjr.20150056
  89. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47(3):551- 560. doi: 10.1016/s0360-3016(00)00467-3
  90. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25(9):1054-1060. doi: 10.1200/JCO.2006.09.3484
  91. Moraitis A, Prochnow A, Poeppel TD, et al. Tumor dose– response relationship of [¹³¹I]MIBG therapy in patients with neural crest tumors by means of [¹²⁴I]MIBG PET. J Nucl Med. 2025;66(4):641‑647. doi: 10.2967/jnumed.124.269377
  92. Mairs RJ, Boyd M. Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy. Nucl Med Biol. 2008;35:S9-S20. doi: 10.1016/j.nucmedbio.2008.04.008
  93. Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer. 2014;50(4):801-815. doi: 10.1016/j.ejca.2013.11.016
  94. Mutic S, Palta JR, Butker EK, et al. Quality assurance for computed-tomography simulators and the computed-tomography-simulation process: report of the AAPM Radiation Therapy Committee Task Group No. 66. Med Phys. 2003;30(10):2762-2792. doi: 10.1118/1.1609271
  95. Hurkmans CW, Remeijer P, Lebesque JV, Mijnheer BJ. Set-up verification using portal imaging; review of current clinical practice. Radiother Oncol. 2001;58(2):105-120. doi: 10.1016/s0167-8140(00)00260-7
  96. Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? Lancet Oncol. 2006;7(11):935-943. doi: 10.1016/S1470-2045(06)70940-8
  97. Lamb BW, Sevdalis N, Mostafid H, Vincent C, Green JS. Quality improvement in multidisciplinary cancer teams: an investigation of teamwork and clinical decision-making and cross-validation of assessments. Ann Surg Oncol. 2011;18(13):3535-3543. doi: 10.1245/s10434-011-1773-5
  98. Kesson EM, Allardice GM, George WD, Burns HJ, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2012;344(apr26 1):e2718. doi: 10.1136/bmj.e2718
  99. Hillner BE, Siegel BA, Hanna L, et al. Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts. J Nucl Med. 2012;53(5):831-837. doi: 10.2967/jnumed.112.103911
  100. Donabedian A. Evaluating the quality of medical care. 1966. Milbank Q. 2005;83(4):691-729. doi: 10.1111/j.1468-0009.2005.00397.x
  101. Kurtzman ET, Corrigan JM. Measuring the contribution of nursing to quality, patient safety, and health care outcomes. Policy Polit Nurs Pract. 2007;8(1):20-36. doi: 10.1177/1527154407302115
  102. Capala J, Graves SA, Scott A, et al. Dosimetry for radiopharmaceutical therapy: current practices and commercial resources. J Nucl Med. 2021;62(suppl 3):3S-11S. doi: 10.2967/jnumed.121.262749
  103. Wolf JA, Niederhauser V, Marshburn D, LaVela SL. Defining patient experience. Patient Exp J. 2014;1(1):7‑19. doi: 10.35680/2372‑0247.1004
  104. Fabian A, Rühle A, Domschikowski J, et al. Satisfaction with radiotherapy care among cancer patients treated in Germany-secondary analysis of a large multicenter study. Strahlenther Onkol. 2024;200(6):487-496. doi: 10.1007/s00066-023-02176-5
  105. Makary MA, Daniel M. Medical error-the third leading cause of death in the US. BMJ. 2016;353:i2139. doi: 10.1136/bmj.i2139
  106. Barach P, Small SD. Reporting and preventing medical mishaps: lessons from non-medical near miss reporting systems. BMJ. 2000;320(7237):759-763. doi: 10.1136/bmj.320.7237.759
  107. Reason J. Human error: models and management. BMJ. 2000;320(7237):768-770. doi: 10.1136/bmj.320.7237.768
  108. Mariani G, Bruselli L, Kuwert T, et al. A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging. 2010;37(10):1959-1985. doi: 10.1007/s00259-010-1390-8
  109. Bailey DL, Willowson KP. Quantitative SPECT/CT: SPECT joins PET as a quantitative imaging modality. Eur J Nucl Med Mol Imaging. 2014;41(S1):S17-S25. doi: 10.1007/s00259-013-2542-4
  110. Herrmann K, Schwaiger M, Lewis JS, et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 2020;21(3):e146-e156. doi: 10.1016/S1470-2045(19)30821-6
  111. Bodei L, Herrmann K, Schöder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19(8):534- 550. doi: 10.1038/s41571-022-00652-y
  112. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125-135. doi: 10.1056/NEJMoa1607427
  113. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-1103. doi: 10.1056/NEJMoa2107322
  114. Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL. Artificial intelligence in radiology. Nat Rev Cancer. 2018;18(8):500-510.doi: 10.1038/s41568-018-0016-5
  115. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44- 56. doi: 10.1038/s41591-018-0300-7
  116. Dorsey ER, Topol EJ. State of Telehealth. N Engl J Med. 2016;375(2):154-161. doi: 10.1056/NEJMra1601705
  117. Hollander JE, Carr BG. Virtually Perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679-1681. doi: 10.1056/NEJMp2003539
  118. Eberlein U, Cremonesi M, Lassmann M. Individualized dosimetry for theranostics: necessary, nice to have, or counterproductive? J Nucl Med. 2017;58(suppl 2):97S-103S. doi: 10.2967/jnumed.116.186841
  119. O’Donoghue J, Zanzonico P, Humm J, Kesner A. Dosimetry in Radiopharmaceutical Therapy. J Nucl Med. 2022;63(10):1467-1474. doi: 10.2967/jnumed.121.262305
  120. Reeves S, Perrier L, Goldman J, Freeth D, Zwarenstein M. Interprofessional education: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2013;2018(8). doi: 10.1002/14651858.cd002213.pub3
  121. Hammick M, Freeth D, Koppel I, Reeves S, Barr H. A best evidence systematic review of interprofessional education: BEME Guide no. 9. Med Teach. 2007;29(8):735-751. doi: 10.1080/01421590701682576
  122. Gaba DM. The future vision of simulation in health care. Qual Saf Health Care. 2004;13(Suppl 1):i2-i10. doi: 10.1136/qshc.2004.009878
  123. Cook DA, Hatala R, Brydges R, et al. Technology-enhanced simulation for health professions education: a systematic review and meta-analysis. JAMA. 2011;306(9):978-988. doi: 10.1001/jama.2011.1234
  124. Polit DF, Beck CT. Nursing Research: Generating and Assessing Evidence for Nursing Practice. 10th ed. Wolters Kluwer. 2017.
  125. Mason DJ, Gardner DB, Outlaw FH, O’Grady ET. Policy and Politics in Nursing and Health Care. 7th ed. Elsevier. 2015. Available from: https://shop.elsevier.com/books/policy-and-politics-in-nursing-and-health-care/mason/978-0- 323-24144-1 [Last accessed on February 26, 2026].
  126. Milstead JA, Short NM. Health Policy and Politics: A Nurse’s Guide. 6th ed. Jones and Bartlett. 2019. Available from: https://catalog.nlm.nih.gov/discovery/fulldisplay/ alma9917079413406676/01NLM_INST:01NLM_INST [Last accessed on February 26, 2026].
  127. Pryma DA, Chin BB, Noto RB, et al. Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J Nucl Med. 2019;60(5):623-630. doi: 10.2967/jnumed.118.217463
Next article in this issue
Share
Back to top
Advances in Radiotherapy & Nuclear Medicine, Electronic ISSN: 2972-4392 Print ISSN: 3060-8554, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept